Yassine Bendiabdallah - Pasithea Therapeutics COO Clinics
| KTTA Stock | USD 2.90 0.11 3.65% |
Insider
Yassine Bendiabdallah is COO Clinics of Pasithea Therapeutics Corp
| Age | 40 |
| Address | 1111 Lincoln Road, Miami Beach, FL, United States, 33139 |
| Phone | 702 514 4174 |
| Web | https://www.pasithea.com |
Pasithea Therapeutics Management Efficiency
The company has return on total asset (ROA) of (0.379) % which means that it has lost $0.379 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.6325) %, meaning that it created substantial loss on money invested by shareholders. Pasithea Therapeutics' management efficiency ratios could be used to measure how well Pasithea Therapeutics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.9. In addition to that, Return On Capital Employed is expected to decline to -0.71. At present, Pasithea Therapeutics' Total Assets are projected to increase significantly based on the last few years of reporting. The current year's Net Tangible Assets is expected to grow to about 62.1 M, whereas Non Current Assets Total are forecasted to decline to about 5.7 M.Similar Executives
| Showing other executives | INSIDER Age | ||
| MBA MD | Eliem Therapeutics | 63 | |
| James Foster | Virax Biolabs Group | 39 | |
| Cameron Shaw | Virax Biolabs Group | 37 | |
| Eugene Jiang | ABVC Biopharma | 38 | |
| Angela Nelms | RenovoRx | 47 | |
| ChiHsin King | ABVC Biopharma | 76 | |
| MaryJane Rafii | Kiora Pharmaceuticals | N/A | |
| Michael Newman | Indaptus Therapeutics | 68 | |
| Joshua Kazam | Kronos Bio | 47 | |
| MD MPH | MediciNova | 56 | |
| Boyan MD | Indaptus Therapeutics | 57 | |
| James Ahlers | RenovoRx | 60 | |
| MD MBA | Kiora Pharmaceuticals | 50 | |
| Denise Carter | Quoin Pharmaceuticals Ltd | 55 | |
| Noreen MD | Kezar Life Sciences | 59 | |
| Dr MBA | MediciNova | 59 | |
| Tomasz George | Virax Biolabs Group | 40 | |
| Robert MBA | Eliem Therapeutics | 56 | |
| Melissa Tosca | Kiora Pharmaceuticals | N/A | |
| Erin Lavelle | Eliem Therapeutics | 47 | |
| Stephanie Yao | Kronos Bio | N/A | |
Management Performance
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.38 |
Pasithea Therapeutics Leadership Team
Elected by the shareholders, the Pasithea Therapeutics' board of directors comprises two types of representatives: Pasithea Therapeutics inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Pasithea. The board's role is to monitor Pasithea Therapeutics' management team and ensure that shareholders' interests are well served. Pasithea Therapeutics' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Pasithea Therapeutics' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Yassine Bendiabdallah, COO Clinics | ||
| MD BA, Ex CoFounder | ||
| Tiago Marques, CEO Director | ||
| Daniel Schneiderman, Chief Officer | ||
| Tiago MD, CEO Director | ||
| Graeme Currie, Chief Officer | ||
| BA MD, Executive CoFounder |
Pasithea Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Pasithea Therapeutics a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.63 | ||||
| Return On Asset | -0.38 | ||||
| Current Valuation | (8.3 M) | ||||
| Shares Outstanding | 1.27 M | ||||
| Shares Owned By Insiders | 23.12 % | ||||
| Shares Owned By Institutions | 2.86 % | ||||
| Number Of Shares Shorted | 5.11 K | ||||
| Price To Book | 0.21 X | ||||
| Price To Sales | 42.15 X | ||||
| Revenue | 486.56 K |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Pasithea Therapeutics is a strong investment it is important to analyze Pasithea Therapeutics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Pasithea Therapeutics' future performance. For an informed investment choice regarding Pasithea Stock, refer to the following important reports:Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in Pasithea Therapeutics Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pasithea Therapeutics. If investors know Pasithea will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pasithea Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (14.79) | Revenue Per Share 0.37 | Quarterly Revenue Growth 14.981 | Return On Assets (0.38) | Return On Equity (0.63) |
The market value of Pasithea Therapeutics is measured differently than its book value, which is the value of Pasithea that is recorded on the company's balance sheet. Investors also form their own opinion of Pasithea Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Pasithea Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pasithea Therapeutics' market value can be influenced by many factors that don't directly affect Pasithea Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Pasithea Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pasithea Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pasithea Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.